The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases

@article{Wright2015TheDO,
  title={The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases},
  author={John W. Wright and Leen H. Kawas and J. Harding},
  journal={Progress in Neurobiology},
  year={2015},
  volume={125},
  pages={26-46}
}
Alzheimer's (AD) and Parkinson's (PD) diseases are neurodegenerative diseases presently without effective drug treatments. AD is characterized by general cognitive impairment, difficulties with memory consolidation and retrieval, and with advanced stages episodes of agitation and anger. AD is increasing in frequency as life expectancy increases. Present FDA approved medications do little to slow disease progression and none address the underlying progressive loss of synaptic connections and… Expand
Brain angiotensin II and angiotensin IV receptors as potential Alzheimer’s disease therapeutic targets
TLDR
The RAS may provide novel molecular targets for recovering memory pathways, cerebrovascular function, and other pathological landmarks of AD, and putative mechanisms of action underlying ARB’s beneficial effects that may explain their ability to modify the risk of developing AD or AD progression are highlighted. Expand
Recent Development in Synthesis and Pharmacological Evaluation of Small Molecule to Treat Alzheimer's Diseases: A Review Study
Alzheimer's disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. It is a neurodegenerative type of dementia, the disease starts mild and getsExpand
The Development of Small Molecule Angiotensin IV-Based Analogs to Treat Depression
Major depression is a common form of mental disorder affecting approximately 15% of the population at least once during lifetime. The etiology of depression is complex with potential contributionsExpand
Research Progress of Alzheimer's Disease Therapeutic Drugs: Based on Renin-Angiotensin System Axis.
TLDR
The mechanisms of RAS participating in the three current hypotheses of AD: neuroinflammation, oxidative stress and amyloid-β protein (Aβ) hypothesis are discussed, as well as the drugs that regulate RAS systems already in clinical or in clinical trials. Expand
Small molecule activation of the neurotrophin hepatocyte growth factor to treat Alzheimer disease
TLDR
This work presents the strategy of utilizing small molecule analogs specifically designed to penetrate the blood-brain barrier and facilitate dimerization and activation of the HGF/Met receptor system to encourage the formation of new functional synaptic connections, induce long-term potentiation and augment memory consolidation and retrieval in animal models of AD. Expand
Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson’s disease
TLDR
RAS is a promising target for symptomatic and neuroprotective therapies in PD and its potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System in PD will be explored. Expand
Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease
TLDR
This review will provide updated information regarding the current drugs and non-drugs therapies for PD. Expand
Neurovascular and Cognitive failure in Alzheimer’s Disease: Benefits of Cardiovascular Therapy
TLDR
Recent findings suggest that drugs originally designed to treat cardiovascular diseases that concurrently restore cerebrovascular and cognitive function do so through their pleiotropic effects, which may help select medications for patients with cardiovascular diseases at risk of developing AD with increasing age. Expand
Small Molecule AngIV-based Analogs to Treat Alzheimers Disease
TLDR
This family of compounds represents a new class of drugs with lead candidates that are orally active, penetrate the BBB sufficiently to reach therapeutic concentrations, and reverse memory deficits seen in animal models of dementia. Expand
Neuroprotective effects of geniposide on Alzheimer’s disease pathology
TLDR
The possible molecular mechanisms of geniposide to protect the brain from pathologic damages underlying AD are reviewed: reducing amyloid plaques, inhibiting τ phosphorylation, preventing memory impairment and loss of synapses, reducing oxidative stress and the chronic inflammatory response, and promoting neurite outgrowth via the GLP-1R signaling pathway. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 385 REFERENCES
Importance of the Brain Angiotensin System in Parkinson's Disease
TLDR
The hepatocyte growth factor (HGF)/c-Met receptor system is a member of the growth factor family and has been shown to protect against degeneration of DA neurons in animal models and may offer a new and novel approach to the treatment of Parkinson's disease. Expand
The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease
TLDR
A working hypothesis is concluded concerning the importance of the AT4 receptor subtype as a new potential drug target for the treatment of Alzheimer's disease-associated memory loss. Expand
Angiotensin as a target for the treatment of Alzheimer’s disease, anxiety and depression
  • P. Gard
  • Medicine
  • Expert opinion on therapeutic targets
  • 2004
TLDR
These findings suggest that angiotensin receptor ligands may have potential in the prevention or even reversal of vascular dementias and AD and the use of such agents in the treatment of hypertension coexisting with depression or anxiety. Expand
Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease.
TLDR
This observational study suggests that CACE-Is, and potentially perindopril in particular, are associated with a reduced rate of functional decline in patients with AD, without an association with mood or behavior. Expand
A Role for the Brain RAS in Alzheimer’s and Parkinson’s Diseases
TLDR
The development of efficacious AngIV analogs in the treatment of animal models of AD and PD are discussed, which act via the AT4 receptor subtype which may coincide with the hepatocyte growth factor/c-Met receptor system. Expand
Current and Emerging Drug Treatment Options for Alzheimer’s Disease
TLDR
A systematic review critically examines the efficacy and safety data for currently approved drugs and emerging treatments in AD, as well as discussing the present and future directions of innovation in this field. Expand
Is inhibition of the renin–angiotensin system a new treatment option for Alzheimer's disease?
TLDR
Molecular, genetic, and clinical studies that might help explain the relation between the renin-angiotensin system, hypertension, and Alzheimer's disease are explored and whether treatment with angiotENSin converting enzyme (ACE) inhibitors and similar treatment strategies have a part to play in the management of the disease. Expand
The role of the central renin-angiotensin system in Parkinson’s disease
TLDR
Three different strategies to interfere with the pathogenesis or the progression of Parkinson’s disease are discussed, which include inhibition of the angiotensin-converting enzyme, blockade of the AngiotensIn II type 1 receptor and stimulation of theAngiotens in II type 2 receptor. Expand
The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
  • S. Lipton
  • Medicine
  • Current Alzheimer research
  • 2005
TLDR
The molecular mechanism of memantine's action and also the basis for the drug's use in these neurological diseases, which are mediated at least in part by excitotoxicity, are reviewed. Expand
Current treatment and recent clinical research in Alzheimer's disease.
TLDR
Other therapies targeting hyperphosphorylated tau and novel targets such as enhancement of mitochondrial function, serotonin receptors, receptor for advanced glycation end products, and nerve growth factor, as well as other strategies, are discussed. Expand
...
1
2
3
4
5
...